Rick Simpson Oil (RSO) in Pima County: The Complete Guide by OilWell Cannabis

If you’re researching Rick Simpson Oil in Pima County, you’re looking for answers that cut through the noise of internet hype and social media speculation. Maybe you live in Tucson, Oro Valley, or Green Valley. Perhaps you’re a retiree in Sahuarita dealing with chronic pain that prescription meds haven’t touched. You could be a veteran at Davis-Monthan Air Force Base managing PTSD, or a cancer patient at Banner-University Medical Center considering complementary options. Whoever you are, you deserve honest, evidence-based information about what RSO is, what it can and cannot do, and how our modern, multi-cannabinoid formulas differ from what Rick Simpson made in his Nova Scotia backyard twenty years ago.

We created this guide because Pima County residents deserve the same level of transparency and scientific rigor we’ve brought to Houston since 2019. Our community here in the Sonoran Desert faces unique health challenges—extreme UV exposure driving high skin cancer rates, an active outdoor lifestyle that wears on aging joints, and a significant veteran population dealing with service-related trauma. We honor Rick Simpson’s grassroots mission while respecting that Pima County’s healthcare landscape demands precision, safety, and accountability.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. This story resonates powerfully across Pima County, whether you’re in the working-class neighborhoods of South Tucson or the agricultural communities near Marana. When conventional medicine falls short, people seek alternatives—that’s a universal experience that transcends geography.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials . For Pima County residents researching cannabis and cancer, this is a critical point: preclinical mouse studies do not translate directly to human cures, no matter how compelling the initial data appears.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source, making this a purely anecdotal claim that lacks scientific validation . Given Pima County’s exceptionally high skin cancer rates due to our intense desert sun, we must be especially clear: this is not medical evidence, and delaying proven dermatological treatment for unverified home remedies carries serious risks.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement. For Pima County readers, this distinction matters—personal stories can inspire research, but they should not substitute for proven medical care.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others . This free-distribution model resonates with Pima County’s strong tradition of mutual aid and community support, particularly in tight-knit neighborhoods from Barrio Viejo to the Tohono O’odham Nation.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era . Many Tucson residents and Pima County locals first encountered the concept of RSO through this documentary, spreading through cannabis community networks and online forums.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad . This legal conflict parallels experiences many in Pima County have faced, particularly in communities of color disproportionately affected by cannabis enforcement, even as Arizona has moved toward legalization.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions . Pima County readers should understand this protocol was designed for a crude, unstandardized product—not for modern lab-tested formulations.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day. Total daily intake: approximately 30 to 45 milligrams. This slow start builds tolerance gradually.

• Weeks 2 through 5: Double the dose approximately every four days. By the end of this escalation period, the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, until the full 60 grams have been consumed.

Administration methods

• Primary method—oral: Sublingual or swallowed, considered most important for systemic absorption and internal cancers.
• Secondary method—topical: For skin cancers and external lesions, applied directly to affected area with bandages changed every three to four days.
• Not recommended as primary—inhalation: Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained oral route was necessary for sustained, high-dose exposure.

Tolerance and the psychoactive effects

Simpson maintained that patients would develop significant tolerance to psychoactive effects within approximately three to four weeks. He recommended initial nighttime dosing to sleep through the most intense effects and urged patients not to let the high discourage them from continuing. He also warned against driving or operating machinery during titration—advice that remains absolutely critical for Pima County drivers navigating our busy I-10 corridor or rural roads.

Post-protocol maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely. He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and lifestyle recommendations

Simpson advocated for reducing sugar intake, avoiding processed foods, and improving overall nutrition—advice that aligns well with Pima County’s growing farm-to-table movement and emphasis on whole foods.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific 60-gram/90-day protocol for any condition.
• Assumes crude, unstandardized material. Actual THC content per gram of traditional RSO varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 600 to 900 milligrams of delta-9 THC per day—far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [15]. These risks are especially concerning for Pima County’s large senior population, who may be more vulnerable to cognitive impairment and falls.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself. Pima County residents have access to world-class cancer care at Banner-University Medical Center and Tucson Medical Center; any consideration of RSO should complement, not replace, conventional oncology.

Arizona has some of the highest skin cancer rates in the nation due to our intense desert sun . While Simpson’s story about treating basal cell carcinoma with topical RSO may sound appealing, delaying proven dermatological treatments like Mohs surgery or radiation can allow cancers to progress, potentially leading to disfigurement or metastasis. The University of Arizona Cancer Center provides cutting-edge care that should remain the foundation of any cancer treatment plan.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season, much like how traditional herbal medicine varies harvest to harvest. This lack of standardization is a major departure from modern pharmaceutical expectations, including those of informed Pima County consumers.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid or Varsol. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which represents a significant safety issue for Pima County residents who may be considering DIY extraction in their garages or kitchens. Our hot desert climate increases fire risk, and improper ventilation when working with volatile solvents can be deadly.

Extraction process

The eight-step process involved bucket agitation, filtration through cheesecloth, and evaporation in a rice cooker. This method is still replicated by DIY makers worldwide, including here in Pima County’s more rural areas where cannabis cultivation knowledge runs deep. However, the process carries significant risks: fire hazards from volatile solvents, incomplete purging leading to toxic residues, and temperature inconsistency affecting product quality.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with a strong cannabis odor and possible solvent-residual smell. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly. This tar-like appearance is what many Pima County residents expect when they hear “RSO,” but modern formulations look and behave differently.

Cannabinoid profile

Traditional RSO was primarily decarboxylated delta-9 THC, with naturally occurring minor cannabinoids at their natural ratios but no control, measurement, or lab verification. Estimated THC content ranged from 60 to 90 percent by weight, though this was never lab-verified in traditional production contexts. This variability means that two people in Pima County making “traditional RSO” could end up with products that are pharmacologically very different.

Terpene content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content. This is significant because Pima County’s sophisticated cannabis consumers increasingly understand that terpenes matter—not just for flavor and aroma, but for potential synergistic effects.

Standardization and testing

None. Every batch was different because it depended entirely on starting material, growing conditions, solvent purity, extraction technique, and the individual maker’s process. Simpson operated before cannabis legalization and standardized lab-testing infrastructure. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening. This lack of quality control is unacceptable for today’s Pima County consumers who expect the same lab-testing standards they demand from their food and supplements.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, xylene, and other toxic compounds. Isopropyl alcohol, while cleaner, is also not intended for internal consumption. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions . It’s important to evaluate these claims against the actual evidence base.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist and is scientifically interesting but preliminary:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research at institutions worldwide, including research happening at the University of Arizona.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

For Pima County residents, these institutional positions matter because they reflect the consensus of the medical establishment that works within our local healthcare system. The University of Arizona Cancer Center and Banner Health operate according to these evidence standards.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today, including here in Arizona. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. For Pima County residents, this is perhaps the most critical message: explore complementary options, but do not abandon conventional cancer care that has decades of proven success.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Whether the evolution from free distribution to commercial production represents improvement (through quality control, lab testing, and dosing precision) or betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective. What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we offer to Pima County.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach we use in our products available to Pima County residents.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why our formulas diverge from traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic compounds. Isopropyl alcohol, while cleaner, is also not intended for internal consumption. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern extraction methods overwhelmingly use food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to product-quality discussions in our evidence section, which emphasizes that product quality matters as much as molecule identity [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent (60-80°C for naphtha, 82°C for isopropyl alcohol)—was sufficient to convert essentially all THCa into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral cannabinoids.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This intentional formulation choice is informed by the THCa evidence profile, which notes that THCa itself does not produce psychoactive effects associated with THC, but interpretation depends on route, temperature, processing, and storage because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21°C and 157°C. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash; and second, by evaporating them off during the high-heat solvent-removal phase. This meant traditional RSO was essentially a cannabinoid-only product.

Our formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile, and the entourage-effect literature provides the theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically [20][29].

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics.

This document takes a fundamentally different approach. Our evidence section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. Where Simpson relied on personal testimony, we rely on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with our modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90 percent delta-9 THC. Our formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600-900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for our products should be developed independently of Simpson’s protocol, informed by per-compound evidence and responsible titration principles. We provide condition-specific usage contexts later in this guide, but these are educational frameworks, not medical prescriptions.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ)—Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. While our headquarters are in Houston’s Montrose neighborhood, we serve customers nationwide—including every corner of Pima County, from the foothills of the Santa Catalina Mountains to the border communities of Arivaca and Sasabe.

Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. This background isn’t just a biographical detail; it’s why we understand the communities we serve in Pima County. Whether you’re in Nogales dealing with cross-border dynamics or in Tucson’s Barrio Viejo, you know that hardship and resilience often walk the same path. Colin’s childhood was marked by exposure to both opportunities and challenges of life along the border—early experiences that taught him to hustle, but also taught him the value of community and the dangers of the underground economy.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines our approach and sets us apart in serving Pima County’s discerning, health-conscious consumers.

Bentley’s story—our foundation

Our origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, a kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question changed everything.

Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

This real-world formulation testing—conducted over a decade on a beloved companion—created the foundation for our seven-cannabinoid RSO formula. Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. That necessity-born approach now serves Pima County residents dealing with multiple overlapping health challenges.

From personal healing to community mission

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction, a common story among veterans in Pima County’s large military community. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive. Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge—it’s lived experience.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of our work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 recognition and credibility

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. Five different ABC13 reporters sought Colin out across those years. When a major-market ABC affiliate needs to explain cannabis policy, product safety, or community health initiatives, they come to Colin. This third-party validation establishes credibility that no marketing copy could achieve.

From explaining Texas marijuana law and Delta-8 legal analysis to leading COVID-19 community health initiatives and discussing criminal justice reform, Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage. Our quote from that first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Our Houston operations serving Pima County

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston using only our own recipes and ideas.

But our reach extends far beyond Texas. Through our sophisticated shipping infrastructure and PANDEM1C SEO technology—which covers 14 million distinct geopolitical locations across six continents—we serve customers in every corner of Pima County, from the urban core of Tucson to the remote reaches of Organ Pipe Cactus National Monument.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States—including direct to Pima County—and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-source formulas. We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace.

4. Evidence-informed, not evidence-overstating. The research documentation throughout this guide represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework for Arizona

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Arizona.

Important Arizona-specific note: While Arizona has legalized recreational cannabis, hemp-derived products operate under separate federal guidelines. Our products comply with the 2018 Farm Bill, making them legally distinct from Arizona’s state-licensed cannabis program. This means Pima County residents can access our products without a medical card, regardless of whether they qualify for Arizona’s medical marijuana program or prefer to avoid state registration.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

Important legal notice for Pima County customers: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Arizona laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-source formulas—why we publish everything

We publish our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

Our rationale is straightforward: if someone cannot afford our products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. This is a direct echo of Rick Simpson’s original ethos. He gave his oil away for free and taught people how to make it. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As our founder said in that first ABC13 feature in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. Our website publishes the actual CBD golden paste recipe that saved Bentley’s life, so that any Pima County pet owner facing a similar crisis can make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in a jar with lid in the refrigerator for up to two weeks.
4. Add a small amount of CBD oil to the paste before giving to the pet, adjusting dosage based on weight and health needs. Start low and increase gradually.

Serving suggestion: Mix a small amount with pet’s food once or twice daily. Monitor for changes and consult a veterinarian if concerns arise. Always consult a veterinarian before starting any new supplement regimen.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula designed for people. The open-source ethos is not a marketing strategy; it is foundational behavior.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. Our sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment—crucial for Pima County professionals who need functional relief.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45-60 minutes converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC—achieving psychoactive potency comparable to traditional high-THC RSO, 100 percent legally. You may also transfer a controlled portion into a second oven-safe container, decarboxylating only what you intend to use.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids—fastest onset available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of a CO₂ molecule.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their medicine, but implementing that principle through actual product chemistry.

Solvent-free production

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha, no isopropyl alcohol, no butane, no extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website. For Pima County customers, this means every batch has been tested to the same standards required of Arizona’s state-licensed cannabis products.

The broader OilWell product portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—Our most popular product, particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. This resonates deeply with Pima County’s large veteran community at Davis-Monthan AFB and throughout Tucson.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. These helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD.

Custom creations—We offer custom-made products tailored to specific needs: particular cannabinoid ratios, delivery formats, or formulations for unique health circumstances, including vegan and diabetic-friendly options.

Two product formats for Pima County residents

We offer the RSO formula in two delivery formats:

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL dosing
• Onset: 15-45 minutes
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximately 40-60 doses per bottle

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio (auto-decarbs THCa)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

When to use each format in Pima County

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—crucial for breakthrough cancer pain or PTSD episodes
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for managing overnight pain or inflammation from hiking Sabino Canyon
Maximum bioavailability	Sublingual	13-19% absorption—most efficient for systemic effects
Portability and discretion	Vape	Compact, no measuring—easy to carry while exploring Saguaro National Park
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—perfect for titration
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment—function at work or driving
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full-spectrum effects

Competitive comparison—OilWell RSO vs. alternatives relevant to Pima County

OilWell RSO vs. Arizona dispensary RSO

Dimension	Arizona dispensary RSO	OilWell RSO
Cannabinoid profile	THC-dominant (often 70-90% THC)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	Typically minimal	3,000 mg
CBN content	Typically minimal	750 mg
CBC content	Typically minimal	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until you heat it
Access requirements	Arizona medical card or 21+ recreational purchase	Age 21+ only, no medical card required, ships to your door
Delivery	Must travel to dispensary (Tucson, Oro Valley, etc.)	Direct shipping to any Pima County address
Price point	Typically $60-80 per gram	$129.99 for 30mL (16,590mg total cannabinoids)

OilWell RSO vs. hemp CBD RSO

Dimension	Typical hemp RSO (1,000mg)	OilWell RSO (16,590mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	Minimal	3,000 mg
Delta-8 THC	Usually 0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful effect	Yes—via THCa decarboxylation and delta-8 THC

Condition-specific usage context for Pima County residents

Important disclaimer: The following are educational frameworks informed by cannabinoid research, not medical prescriptions. These products are not FDA-approved to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products. Do not operate vehicles or machinery while under the influence.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 antiemetic [9], delta-9 nausea evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis from hiking, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory without impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: delivers 50 mg CBN—dosage level investigated in 2024 sleep literature
• At 1.0 mL: delivers 25 mg CBN—above threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence [16][17]

Anxiety and stress (PTSD, generalized anxiety)

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage evidence [20]

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. This is especially important for Pima County’s senior population, who may be more sensitive to cannabinoid effects.

Delivery and global accessibility to Pima County

We operate the only same-day RSO delivery system in Houston, but our reach extends nationwide to every Pima County address.

Shipping to Pima County:

• All Arizona addresses served via USPS Priority Mail (2-3 business days), FedEx, and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Arizona’s extreme summer heat (critical for maintaining product integrity)
• Signature-required option available

International shipping:
Our THCa legal framework enables international shipping to jurisdictions with compatible hemp laws. For Pima County residents with family in Mexico or Canada, this means we can ship across borders with full documentation, COAs, and customs receipts. The customer accepts all customs and legal responsibility.

PANDEM1C SEO technology:
Our proprietary system with 14 million distinct geopolitical locations and over 300 AI models drives organic search visibility, making our products discoverable to Pima County residents searching in English or Spanish.

How our formulas connect to the evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in our research section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

Our formulas are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated. We hold ourselves to the same evidence standards we apply to the broader field. That is intentional. As Colin said in 2019, people deserve the best possible version of information so they can give it a fair shot and decide for themselves.

OilWell Cannabis is more than a brand—it is a promise to our Pima County customers that we will always strive to deliver the best, most thoughtful cannabis products available. Our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years. This mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography and resonates with discerning Pima County consumers.

Feature Timeline:

1. September 15, 2019—CBD Business Boom: Colin’s foundational quote about not selling snake oil
2. March 22, 2021—Decriminalization: Highlighting ecosystem building and real pain therapy
3. May 24, 2021—Delta-8 THC “Legal Weed”: Iconic “Maybe you want to get high” exchange
4. August 20, 2021—COVID Vaccine Giveaway: $35,000 in product to encourage vaccination
5. October 19, 2021—Delta-8 Ban: Proactive ethical action before enforcement
6. October 7, 2022—Biden Marijuana Pardon: Personal conviction history revealed
7. April 21, 2023—Texas Marijuana Laws: “Renaissance” framing of industry evolution

The through-line—what the media record reveals

Consistency across years: Through every shift in Texas cannabis law, ABC13 returned to Colin as a primary source.

Breadth of expertise: Features span business, health education, product investigation, legal analysis, political commentary, and community advocacy.

Community action: The COVID vaccine giveaway and proactive Delta-8 removal demonstrate community-first values.

Personal stakes: Colin’s cannabis conviction history transforms every feature—this is someone who lived the consequences and built a legal business with integrity.

Evolution: From “local wholesaler” in 2019 to industry authority by 2023, the media record tracks growth of both business and public role.

These features are independently produced, editorially controlled news segments that repeatedly identified Colin as the most credible voice in Houston’s legal cannabis industry. That recognition cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. Only modest evidence exists for chronic pain and multiple-sclerosis-related symptoms [1].
• FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination, and THC-vape lung-injury concerns [1].
• Over-the-counter CBD products may differ from their labels and have been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

Evidence profile: Strongest human evidence in our formula, especially as purified product [1]-[6].

Best supported: Seizure disorders—clear major-example indication [1][2].

Anxiety: 2024 systematic review of 316 participants found significant anxiolytic signal but stressed limited clinical sample [3].

Pain: 2024 systematic review concluded literature is promising but heterogeneous, limiting broad analgesic claims [4].

Sleep: 2023 insomnia review found literature methodologically weak, with few objective sleep assessments [5].

Safety: 2023 systematic review found liver enzyme elevation signal and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy [6]. Also diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications rather than broad wellness claims [1]-[6].

CBG

Evidence profile: Mostly review-level and preclinical; human evidence sparse [7][8].

Pharmacology: Biosynthetic precursor with distinct interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling [7].

Potential areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—but primarily pharmacology-led hypotheses [7][8].

Caution: Commercially sold while evidence base remains thin; claims frequently outrun science [7].

Bottom line: Serious research topic but should be described as promising minor cannabinoid with limited clinical validation [7][8].

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar behavior. Delta-8 is partial CB1 agonist, less potent than delta-9, likely due to weaker CB1 affinity [9].

Public health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials. Noted reports of adverse consequences and regulatory/product-quality concerns [10].

Manufacturing: Chemistry and pharmacology review notes commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, raising product-byproduct and lab-testing questions [11].

Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than consumers realize [9]-[11].

THCa

Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12].

What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant material. Key issue: THCa decarboxylates into THC during heating and can change over time during storage/processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes [12].

Bottom line: Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage [12].

Delta-9 THC

Evidence profile: Strongest human evidence of psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].

Institutionally best supported: NCCIH identifies relevance to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, some MS- and pain-related outcomes, while stressing many other uses remain uncertain [1].

Pain evidence: 2022 systematic review found high-THC products may provide short-term pain benefit but increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics: Inhaled THC: seconds to minutes onset, peaks 15-30 minutes, tapers over few hours. Oral THC: later onset, later peak, longer duration [14].

Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression [15].

Broader safety: Anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns [1][14][15].

Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15].

CBN

Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].

Marketing: Sleep and sedation—reputation widespread but clinical support far thinner than market suggests [16][17].

Best review: 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography to substantiate strong sleep-promoting claims [16].

Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match scale of real-world use; need for better-designed, adequately powered trials remains substantial [17].

Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging/oxidized cannabis chemistry contexts [12].

Bottom line: Clearest example where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19].

Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids; highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting [18].

Older literature: Review summarizing animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance—but not strong evidence for patient-facing claims [19].

Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—mostly from nonhuman/non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens in patch-testing literature [22].

Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, very limited human evidence [20][23].

Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and possible mechanisms, but explicitly states human studies lacking [23].

Interpretation caution: Myrcene often invoked as proven sedative explaining “couch-lock”—stronger claim than human evidence supports [20][23].

Bottom line: Plausible bioactive terpene, but compound-specific clinical claims remain ahead of definitive human proof [23].

Caryophyllene

Evidence profile: Among most mechanistically interesting due to direct cannabinoid-system relevance, but mostly preclinical [24].

Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual and especially relevant pharmacologically [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions discussed, but human clinical confirmation limited [24].

Bottom line: Strongest candidate for terpene with cannabinoid-system significance, but still not clinically proven for common claims [24].

Pinene

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized lack of well-designed clinical trials [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain interesting hypotheses [20][25].

Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

Evidence profile: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while emphasizing lack of robust human trials [25].

Additional literature: Separate reviews discuss possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].

Safety note: Oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing [22][25][26].

Humulene

Evidence profile: Translationally interesting, but still early [20][27].

Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Bottom line: More interesting terpene research target, but far from clinically settled [27].

Terpinolene

Evidence profile: One of least clinically characterized terpenes in this file [20][28].

Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluding terpinolene has range of reported biological effects but evidence base dominated by in silico, in vitro, and animal studies [28].

Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20].

Bottom line: Biologically interesting, but especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting because underexplored, but claims often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics materially affect interpretation [1][10][11][14].
• For THCa, chemistry is destiny: storage and heating can change exposure profile by converting acidic cannabinoids into neutral cannabinoids [12].

Common overstatements to avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Sleep evidence for CBN remains weak and dated, with no strong validated-trial base [16][17].

Overstatement: Myrcene is proven human sedative explaining couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof limited [20][23].

Overstatement: Terpenes have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating/processing can convert THCa into THC [12].

Overstatement: Delta-8 THC is safe because hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, often entangled with manufacturing/testing concerns [9]-[11].

Practical takeaways for our formulas

• CBD and delta-9 THC most evidence-developed
• Delta-8 THC is not trivial—psychoactive cannabinoid with less robust safety/efficacy characterization
• THCa changes meaningfully with processing—should not be interpreted same way in raw vs. heated formats
• CBG, CBN, CBC scientifically credible but clinically immature compared to CBD/THC
• Listed terpenes likely highly relevant to aroma/flavor and potentially some biologic activity, but compound-specific human therapeutic claims should be careful and only where directly supported

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

28. Menezes IA, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

For Pima County customers: This 30mL bottle provides approximately 40-60 doses depending on your individual needs. At 553mg per mL, this is one of the most concentrated legal hemp-derived products available. The graduated dropper allows precise measurement in 0.1mL increments, essential for responsible titration. Arizona’s hot climate means you should store this product in a cool, dark place—consider refrigeration during summer months to preserve terpene integrity.

RSO VAPE CARTRIDGE

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• 510-thread universal battery compatibility

For Pima County customers: This cartridge offers the fastest relief—1-2 minute onset. Ideal for breakthrough pain, acute nausea, or PTSD episodes. The 510-thread design works with standard vape batteries available at any smoke shop in Tucson or Oro Valley. Vaping occurs at 400-450°F, instantly decarboxylating THCa with each puff. Given Arizona’s dry climate, store cartridges upright to prevent leakage.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Pima County customers: These terpenes create a complex sensory experience that reflects our desert environment. The limonene evokes citrus groves of the past, pinene captures the scent of pine forests on Mount Lemmon, and caryophyllene’s peppery note complements the spicy flavors of our local cuisine. Beyond aroma, each terpene contributes to the entourage effect, potentially modulating how cannabinoids interact with your endocannabinoid system.

Contact Information for Pima County Customers:

Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/
Instagram: @oilwellcbd

Hours:
Monday-Thursday: 10:00 AM – 7:00 PM CST
Friday-Saturday: 10:00 AM – 10:00 PM CST
Sunday: 10:00 AM – 4:00 PM CST

Shipping: We ship daily to all Pima County addresses via USPS, FedEx, and UPS. Arizona orders typically arrive in 2-5 business days.

Legal Disclaimer for Arizona and Pima County: These products contain less than 0.3% delta-9 THC and are Farm Bill compliant. They have not been evaluated by the FDA for safety or efficacy. You must be 21+ to purchase. Keep out of reach of children. Do not operate vehicles or machinery while using psychoactive cannabinoids. Consult a healthcare provider before use, especially if pregnant, nursing, taking medications, or have medical conditions. Customer assumes responsibility for compliance with Arizona law regarding THCa decarboxylation. Product contains no nicotine or tobacco. All products ship with complete Certificates of Analysis.